METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER
First Claim
1. A method of treating advanced stage prostate cancer, the method comprising administering a compound to a patient in need thereof, wherein the prostate cancer is hormone refractory and/or metastatic and the compound is selected from the group consisting of:
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
-
Citations
20 Claims
- 1. A method of treating advanced stage prostate cancer, the method comprising administering a compound to a patient in need thereof, wherein the prostate cancer is hormone refractory and/or metastatic and the compound is selected from the group consisting of:
-
17. A method of treating advanced stage prostate cancer, the method comprising administering to a patient having hormone refractory and/or metastatic prostate cancer a compound selected from the group consisting of:
- N-methyl-Δ
3,3′
-dihydroindole-2,2′
diketone;
N-1-(β
-D-β
-triacetyl-xylopranosyl)-Δ
3,3′
-dihydroindole-2,2′
diketone;
or N-1-(β
-D-O-triacetyl-xylopranosyl)-N′
-methyl-Δ
3,3′
-dihydroindole-2,2′
diketone, wherein the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. - View Dependent Claims (18, 19, 20)
- N-methyl-Δ
Specification